Abstract
Background: Glioblastoma (GBM) has a high degree of malignancy, aggressiveness and recurrence rate. However, there are limited options available for the treatment of GBM, and they often result in poor prognosis and unsatisfactory outcomes.Materials and methods: In order to identify potential core genes in GBM that may provide new therapeutic insights, we analyzed three gene chips (GSE2223, GSE4290 and GSE50161) screened from the GEO database. Differentially expressed genes (DEG) from the tissues of GBM and normal brain were screened using GEO2R. To determine the functional annotation and pathway of DEG, Gene Ontology (GO) and KEGG pathway enrichment analysis were conducted using DAVID database. Protein interactions of DEG were visualized using PPI network on Cytoscape software. Next, 10 Hub nodes were screened from the differentially expressed network using MCC algorithm on CytoHubba software and subsequently identified as Hub genes. Finally, the relationship between Hub genes and the prognosis of GBM patients was described using GEPIA2 survival analysis web tool.Results: A total of 37 up-regulated and 187 down-regulated genes were identified through microarray analysis. Amongst the 10 Hub genes selected, SV2B appeared to be the only gene associated with poor prognosis in glioblastoma based on the survival analysis.Conclusion: Our study suggests that high expression of SV2B is associated with poor prognosis in GBM patients. Whether SV2B can be used as a new therapeutic target for GBM requires further validation.
Highlights
Glioblastoma multiforme (GBM) is an end-stage glioma disease with an annual incidence of 3.19 cases per 100,000 in the United States
Enrichment analysis was performed using DAVID database tool to identify the functions of Differentially expressed genes (DEG) involved in one or more of the following processes: biological process (BP), cellular component (CC) and molecular function (MF)
Our analysis revealed that DEGs were mainly enriched in axonogenesis and calcium ion binding of BP and MF, respectively
Summary
Glioblastoma multiforme (GBM) is an end-stage glioma disease with an annual incidence of 3.19 cases per 100,000 in the United States. Despite advancements in the development of therapeutics for GBM to date, patient survival still remains poor. A GBM patient receiving TTF combination therapy has survived for more than 5 years, the high treatment cost of $20,000/month is prohibitive for many people [3]. Expressed genes (DEG) from the tissues of GBM and normal brain were screened using GEO2R. The relationship between Hub genes and the prognosis of GBM patients was described using GEPIA2 survival analysis web tool. Amongst the 10 Hub genes selected, SV2B appeared to be the only gene associated with poor prognosis in glioblastoma based on the survival analysis. Conclusion: Our study suggests that high expression of SV2B is associated with poor prognosis in GBM patients. Whether SV2B can be used as a new therapeutic target for GBM requires further validation
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
